A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis

Annals of Neurology

Volumn 72, Issue 2, 2012, Pages 199-210

  Sühs, Kurt Wolfram ^a,b   Hein, Katharina ^c   Sättler, Muriel B ^c   Görlitz, Anke ^d   Ciupka, Christoph ^c   Scholz, Kerstin ^e   Käsmann Kellner, Barbara ^a   Papanagiotou, Panagiotis ^a   Schäffler, Nina ^f   Restemeyer, Cordula ^f   Bittersohl, Diana ^f   Hassenstein, Andrea ^f   Seitz, Berthold ^a   Reith, Wolfgang ^a   Fassbender, Klaus ^a   Hilgers, Reinhard ^c   Heesen, Christoph ^f   Bähr, Mathias ^c   Diem, Ricarda ^a,g  

^a SAARLAND UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Institute for Clinical Studies   (Germany)

^e Lüneburg Psychiatric Hospital   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; NEUROPROTECTIVE AGENT; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EVOKED VISUAL RESPONSE; FEMALE; FLUSHING; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPERGLYCEMIA; INTENTION TO TREAT ANALYSIS; LATENT PERIOD; MALE; MOOD CHANGE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE ATROPHY; OPTIC NEURITIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINAL NERVE FIBER LAYER THICKNESS; SIDE EFFECT; VISUAL ACUITY; VISUAL FIELD; VISUAL SYSTEM PARAMETERS;

ADULT; ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MIDDLE AGED; OPTIC NERVE; OPTIC NEURITIS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS; YOUNG ADULT;

EID: 84865607007     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23573     Document Type: Article

References (36)

1. Frohman EM, Filippi M, Stuve O, et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 2005; 62: 1345-1356. (Pubitemid 41352050)
2. Aktas O, Kieseier B, Hartung HP,. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 2010; 33: 140-152.
3. Hickman SJ, Dalton CM, Miller DH, Plant GT,. Management of acute optic neuritis. Lancet 2002; 360: 1953-1962. (Pubitemid 35472140)
4. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005; 58: 383-391. (Pubitemid 41266624)
5. Henderson AP, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010; 133: 2592-2602.
6. Hickman SJ, Toosy AT, Jones SJ, et al. A serial MRI study following optic nerve mean area in acute optic neuritis. Brain 2004; 127: 2498-2505. (Pubitemid 39472978)
7. Frohman EM, Fujimoto J, Frohman TC, et al. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 2008; 4: 664-675.
8. Diem R, Hobom M, Maier K, et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 2003; 23: 6993-7000. (Pubitemid 36975865)
9. Linker R, Mäurer M, Gaupp S, et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002; 8: 620-624. (Pubitemid 34633441)
10. Hobom M, Storch MK, Weissert R, et al. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol 2004; 14: 148-157. (Pubitemid 38656386)
11. Linker R, Lee DH, Demir S, et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010; 133 (pt 8): 2248-2263.
12. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000; 97: 10526-10531.
13. Sättler MB, Merkler D, Maier K, et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004; 11 (suppl 2): S181-S192.
14. Diem R, Sättler MB, Merkler D, et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005; 128: 375-385. (Pubitemid 40222606)
15. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505. (Pubitemid 36337492)
16. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59: 963-969. (Pubitemid 43830928)
17. Bauer P, Köhne K,. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029-1041.
18. Brunner E, Langer F,. Nichtparametrische Analyse longitudinaler Daten. Munich, Germany; Vienna, Austria: R. Oldenburg-Verlag, 1999: 130-143
19. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 58: 840-846. (Pubitemid 41746873)
20. Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007; 130: 2577-2588. (Pubitemid 47511714)
21. Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010; 9: 921-932.
22. Gold R, Hartung HP, for the Guideline Commission of the German Neurological Society. Leitlinien für Diagnostik und Therapie der multiplen Sklerose. In:, Diener HC, Putzki N, eds. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, Germany: Goerg Thieme Verlag, 2008: 364-381.
23. Nakamura M, Nakazawa T, Doi H, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Opthalmol 2010; 248: 1777-1785.
24. Li W, Maeda Y, Yuan RR, et al. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 2004; 56: 767-777. (Pubitemid 39578439)
25. Siren AL, Fasshauer T, Bartels C, Ehrenreich H,. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009; 6: 108-127.
26. Zechariah, ElAli A, Hermann DM,. Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke 2010; 41: 1008-1012.
27. Imai Y, Fukuoa T, Nakantani A, et al. Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony-stimulating factor and erythropoietin) and high-dose methylprednisolone. Br J Haematol 1996; 93: 146-150.
28. Tsiara SN, Chaidos A, Gouva M, et al. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolene. J Exp Clin Cancer Res 2004; 23: 47-52. (Pubitemid 38552597)
29. Pollock C, Johnson DW, Hörl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008; 3: 193-199.
30. Baier ML, Cutter GR, Rudick RA, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 2005; 22: 992-995. (Pubitemid 40388449)
31. Talman LS, Bisker ER, Sackel DJ, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in MS. Ann Neurol 2010; 67: 749-760.
32. Rucker JC, Sheliga BM, Fitzgibbon EJ, et al. Contrast sensitivity, first-order motion and initial ocular following in demyelinating optic neuropathy. J Neurol 2006; 253: 1203-1209. (Pubitemid 44511479)
33. Moura AL, Teixeira RA, Oiwa NN, et al. Chromatic discrimination losses in multiple sclerosis patients with and without optic neuritis using the Cambridge Colour Test. Vis Neurosci 2008; 25: 463-468. (Pubitemid 351948118)
34. Meyer R, Weissert R, Diem R, et al. Acute neuronal apoptosis in a rat model of multiple sclerosis. J Neurosci 2001; 21: 6214-6220. (Pubitemid 32737753)
35. Gordon-Lipkin E, Chodkowski B, Reich DS, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 2007; 69: 1603-1609. (Pubitemid 350287144)
36. Frohmann E, Costello F, Zivadinov R, et al. Optical coherence tomography in multiple sclerosis. Lancet Neurol 2006; 5: 853-863. (Pubitemid 44715820)